It was reported on September 11 that Apollo Global Management, Inc. (NYSE:APO) is in discussions to acquire Johnson & Johnson (NYSE:JNJ)’s orthopedics business, DePuy Synthes, in a potential transaction valuing the unit at close to $20 billion, according to Bloomberg. The unit, which J&J previously announced plans to separate within an 18-to-24-month timeframe, generated $9.3 billion in 2025 revenue. An agreement could be reached within weeks, though J&J is also weighing a tax-efficient public market spin-off.
You Might Also Want to Read: Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
Bull Case: Expanding Capital Base Meets High-Margin Focus
For Apollo Global Management, Inc., acquiring a scaled, world-leading orthopedics franchise directly aligns with its large origination engine, committed transaction pipeline, and substantial dry powder. A $20 billion purchase price, equating to ~2.2x 2025 revenue, presents an attractive valuation for a stable asset, giving Apollo significant room to improve operational efficiencies and leverage its expanding capital solutions platform. Deploying capital into scaled medical technology supports long-term revenue visibility, generating predictable cash flows and expanding its fee-generating asset base alongside high-growth perpetual capital.
For Johnson & Johnson, an upfront cash sale accelerates its strategic pivot away from slower-growth segments and toward higher-growth, higher-margin areas like Oncology, Immunology, and Cardiovascular. Selling the unit directly bolsters J&J’s already robust cash generation and conservative balance sheet, providing immediate liquidity for targeted M&A and R&D pipeline expansion without increasing debt. This flexibility allows J&J to reinforce its diversified high-growth product mix while defending its industry-leading operating margins.
Bear Case: Realization and Operational Risks vs. Sacrificed Upside
For Apollo, absorbing DePuy Synthes exposes investors to operational headwinds, ongoing medical device litigation liabilities, and execution complexity. Integrating a heavily restructured orthopedics unit creates near-term earnings risk if margin turnaround targets miss expectations. Furthermore, financing a $20 billion transaction could elevate rising strategic expenses, while any delayed asset monetizations or variable exits across Apollo’s private equity portfolio could test total profitability consistency if macroeconomic growth moderates.
For Johnson & Johnson, divesting DePuy Synthes after incurring heavy restructuring expenses means sacrificing the long-term cash flows of a massive, established franchise. While the sale mitigates exposure to MedTech procedure sensitivity and regional inventory distortions, J&J risks receiving less long-term value than a public spin-off might yield once the standalone business normalizes. Moreover, near-term transaction accounting adjustments could temporarily dilute earnings power, right as J&J navigates steep revenue declines from legacy biologic biosimilar competition like STELARA.
Don’t Miss: Apollo (APO) Nears a 16% Stake in the Yankees. Why Private Equity Wants a Piece of Baseball
Conclusion
A deal offers clear strategic benefits for both companies: Johnson & Johnson unlocks immediate liquidity to concentrate on its highest-margin therapeutic pipelines, while Apollo Global Management, Inc. secures a defensive, cash-generative healthcare anchor to expand its fee-generating asset engine.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
